CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive Vice President, Research and Development (R&D). Dr. Backstrom joins Acceleron from Celgene Corporation, where he most recently served as Chief Medical Officer (CMO).
“During his time at Celgene, I personally found Jay to be an outstanding partner and collaborator, and I couldn’t be more thrilled to be working alongside him,” said Habib Dable, President and Chief Executive Officer of Acceleron. “He was instrumental in helping us bring REBLOZYL®, Acceleron’s first approved medicine, to patients, so we’re truly fortunate to have someone with Jay’s depth and breadth of experience to lead our corporate R&D strategy as we usher Acceleron into an exciting new phase.”
Dr. Backstrom brings to Acceleron nearly three decades of global clinical and regulatory experience in preparing and executing development strategies leading to regulatory approvals across a broad range of therapeutic areas, including hematologic, oncologic, immunologic, cardiovascular, and pulmonary diseases.
Dr. Backstrom joined Celgene in 2008 as Vice President, Clinical R&D with a focus in hematology/oncology, later advancing to the position of CMO and Head of Regulatory Affairs. Prior to Celgene, he served as Vice President, Global Medical Affairs and Safety at Pharmion. Dr. Backstrom began his career in industry in 1990 at Marion Merrell Dow and continued as part of its successor companies including Hoechst Marion Roussel, where he held positions in Clinical Research and Global Drug Surveillance and Pharmacoepidemiology. He also spent nearly three years at Quintiles in Medical and Scientific Services, including Therapeutic Head, Cardiovascular, Respiratory and Critical Care where he oversaw extensive clinical work across a variety of cardiovascular and pulmonary diseases.
Dr. Backstrom served as staff physician and Medical Director of the Samuel U. Rodgers Community Health Center in Kansas City, Missouri. Dr. Backstrom holds an M.D. from Temple University School of Medicine and received post-graduate training in Internal Medicine at Temple University Hospital. He also earned a Master’s in Public Health from Saint Louis University School of Public Health.
“It’s a privilege to be joining a company I know so well and have long admired,” said Dr. Backstrom. “I’ve witnessed first-hand the impact Acceleron’s expertise in TGF-beta superfamily biology could have in the hematology space, and so I now look forward to helping the Company further develop and fully realize the potential of its pipeline in additional therapeutic areas.”
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.